2 Years After Germany's Regulation For Digital Health Apps, What Can We Learn?
At the end of 2019, the Digital Healthcare Act (Digitales Versorgungsgesetz, DVG) introduced a dedicated pathway enabling reimbursement of digital health...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Dr. Myriam Mirza is an associate principal in the Life Sciences Practice of CRA. She has over seven years consulting experience in the life sciences field including healthcare, medical devices, pharmaceuticals, and non-profits.
Prior to joining CRA, Dr. Mirza was a freelance senior healthcare strategic consultant and analyst where she managed teams across the US to implement rare disease clinical programs and consulting European and US clients on market entry, access, and expansion strategies. She has presented at board meetings, international conferences, and has been invited as a rare disease keynote speaker on numerous occasions.